



ELSEVIER

Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox

Short Review

RIFM fragrance ingredient safety assessment, terpinyl isobutyrate, CAS Registry Number 7774-65-4

A.M. Api^a, D. Belsito^b, D. Botelho^a, M. Bruze^c, G.A. Burton Jr.^d, J. Buschmann^e, M.L. Dagli^f, M. Date^a, W. Dekant^g, C. Deodhar^a, M. Francis^a, A.D. Fryer^h, L. Jones^a, K. Joshi^a, S. La Cava^a, A. Lapczynski^a, D.C. Lieblerⁱ, D. O'Brien^a, A. Patel^a, T.M. Penning^j, G. Ritacco^a, J. Romine^a, N. Sadekar^a, D. Salvito^a, T.W. Schultz^k, I.G. Sipes^l, G. Sullivan^{a,*}, Y. Thakkar^a, Y. Tokura^m, S. Tsang^a

^a Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ, 07677, USA

^b Member RIFM Expert Panel, Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Ave., New York, NY, 10032, USA

^c Member RIFM Expert Panel, Malmo University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmo, SE, 20502, Sweden

^d Member RIFM Expert Panel, School of Natural Resources & Environment, University of Michigan, Dana Building G110, 440 Church St., Ann Arbor, MI, 48109, USA

^e Member RIFM Expert Panel, Fraunhofer Institute for Toxicology and Experimental Medicine, Nikolai-Fuchs-Strasse 1, 30625, Hannover, Germany

^f Member RIFM Expert Panel, University of Sao Paulo, School of Veterinary Medicine and Animal Science, Department of Pathology, Av. Prof. dr. Orlando Marques de Paiva, 87, Sao Paulo, CEP 05508-900, Brazil

^g Member RIFM Expert Panel, University of Wuerzburg, Department of Toxicology, Versbacher Str. 9, 97078, Wuerzburg, Germany

^h Member RIFM Expert Panel, Oregon Health Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

ⁱ Member RIFM Expert Panel, Vanderbilt University School of Medicine, Department of Biochemistry, Center in Molecular Toxicology, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN, 37232-0146, USA

^j Member of RIFM Expert Panel, University of Pennsylvania, Perelman School of Medicine, Center of Excellence in Environmental Toxicology, 1316 Biomedical Research Building (BRB) II/III, 421 Curie Boulevard, Philadelphia, PA, 19104-3083, USA

^k Member RIFM Expert Panel, The University of Tennessee, College of Veterinary Medicine, Department of Comparative Medicine, 2407 River Dr., Knoxville, TN 37996-4500, USA


^l Member RIFM Expert Panel, Department of Pharmacology, University of Arizona, College of Medicine, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ, 85724-5050, USA

^m Member RIFM Expert Panel, The Journal of Dermatological Science (JDS), Editor-in-Chief, Professor and Chairman, Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan

Version: 030518. This version replaces any previous versions.

Name: Terpinyl isobutyrate

CAS Registry Number: 7774-65-4

**Abbreviation/Definition List:**

2-Box Model - A RIFM, Inc. proprietary *in silico* tool used to calculate fragrance air exposure concentration

AF - Assessment Factor

BCF - Bioconcentration Factor

* Corresponding author.

E-mail address: gsullivan@rifm.org (G. Sullivan).

<https://doi.org/10.1016/j.fct.2018.10.014>

Received 17 April 2018; Received in revised form 29 August 2018; Accepted 3 October 2018

0278-6915/© 2018 Elsevier Ltd. All rights reserved.

Creme RIFM Model - The Creme RIFM Model uses probabilistic (Monte Carlo) simulations to allow full distributions of data sets, providing a more realistic estimate of aggregate exposure to individuals across a population (Comiskey et al., 2015, 2017; Safford et al., 2015, 2017) compared to a deterministic aggregate approach

DEREK - Derek Nexus is an *in silico* tool used to identify structural alerts

DST - Dermal Sensitization Threshold

ECHA - European Chemicals Agency

EU - Europe/European Union

GLP - Good Laboratory Practice

IFRA - The International Fragrance Association

LOEL - Lowest Observable Effect Level

MOE - Margin of Exposure

MPPD - Multiple-Path Particle Dosimetry. An *in silico* model for inhaled vapors used to simulate fragrance lung deposition

NA - North America

NESIL - No Expected Sensitization Induction Level

NOAEC - No Observed Adverse Effect Concentration

NOAEL - No Observed Adverse Effect Level

NOEC - No Observed Effect Concentration

NOEL - No Observed Effect Level

OECD - Organisation for Economic Co-operation and Development

OECD TG - Organisation for Economic Co-operation and Development Testing Guidelines

PBT - Persistent, Bioaccumulative, and Toxic

PEC/PNEC - Predicted Environmental Concentration/Predicted No Effect Concentration

QRA - Quantitative Risk Assessment

REACH - Registration, Evaluation, Authorisation, and Restriction of Chemicals

RfD - Reference Dose

RIFM - Research Institute for Fragrance Materials

RQ - Risk Quotient

Statistically Significant - Statistically significant difference in reported results as compared to controls with a $p < 0.05$ using appropriate statistical test

TTC - Threshold of Toxicological Concern

UV/Vis spectra - Ultraviolet/Visible spectra

VCF - Volatile Compounds in Food

VoU - Volume of Use **vPvB** - (very) Persistent, (very) Bioaccumulative

WOE - Weight of Evidence

The Expert Panel for Fragrance Safety* concludes that this material is safe under the limits described in this safety assessment.

This safety assessment is based on the RIFM Criteria Document (Api et al., 2015), which should be referred to for clarifications.

Each endpoint discussed in this safety assessment includes the relevant data that were available at the time of writing (version number in the top box is indicative of the date of approval based on a 2-digit month/day/year), both in the RIFM database (consisting of publicly available and proprietary data) and through publicly available information sources (e.g., SciFinder and PubMed). Studies selected for this safety assessment were based on appropriate test criteria, such as acceptable guidelines, sample size, study duration, route of exposure, relevant animal species, most relevant testing endpoints, etc. A key study for each endpoint was selected based on the most conservative endpoint value (e.g., PNEC, NOAEL, LOEL, and NESIL).

*The Expert Panel for Fragrance Safety is an independent body that selects its own members and establishes its own operating procedures. The Expert Panel is comprised of internationally known scientists that provide RIFM with guidance relevant to human health and environmental protection.

Summary: The use of this material under current conditions is supported by existing information.

The material (terpinyl isobutyrate) was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, as well as environmental safety. Data on the read-across analog α -terpineol acetate (CAS# 80-26-2) show that terpinyl isobutyrate is not genotoxic. Data on the read-across analog terpinyl acetate (isomer mixture; CAS# 8007-35-0) show that terpinyl isobutyrate is not a concern for skin sensitization and provided an MOE > 100 for the repeated dose toxicity endpoint. The respiratory toxicity endpoint was completed using the TTC (Threshold of Toxicological Concern) for a Cramer Class I material (1.4 mg/day). The developmental and reproductive toxicity endpoint was completed using terpineol (CAS# 8000-41-7) and isobutyric acid (CAS# 79-31-2) as read-across analogs, which provided an MOE > 100. The phototoxicity/photoallergenicity endpoint was completed based on UV spectra. The environmental endpoints were evaluated, terpinyl isobutyrate was found not to be PBT as per the IFRA Environmental Standards, and its risk quotients, based on its current volume of use in Europe and North America (i.e., PEC/PNEC), are < 1.

Human Health Safety Assessment

Genotoxicity: Not genotoxic.

(RIFM, 2014b; RIFM, 2014c)

Repeated Dose Toxicity: NOAEL = 400 mg/kg/day.

(Hagan et al., 1967)

Developmental and Reproductive Toxicity: NOAEL = 200 and 250 mg/kg/day, respectively.

(ECHA Dossier: Terpineol)

Skin Sensitization: Not a concern for skin sensitization.

(RIFM, 2012b)

Phototoxicity/Photoallergenicity: Not phototoxic/photoallergenic.

(UV Spectra, RIFM DB)

Local Respiratory Toxicity: No NOAEC available. Exposure is below the TTC.

Environmental Safety Assessment**Hazard Assessment:****Persistence:** Screening-level: 2.6 (BIOWIN 3)

(EPI Suite v4.11; US EPA, 2012a)

Bioaccumulation: Screening-level: 1344 L/kg

(EPI Suite v4.11; US EPA, 2012a)

Ecotoxicity: Screening-level: 96-h Algae EC50: 0.143 mg/L

(ECOSAR; US EPA, 2012b)

Conclusion: Not PBT or vPvB as per IFRA Environmental Standards**Risk Assessment:****Screening-level:** PEC/PNEC (North America and Europe) > 1

(RIFM Framework; Salvito et al., 2002)

Critical Ecotoxicity Endpoint: 96-h Algae EC50: 0.143 mg/L

(ECOSAR; US EPA, 2012b)

RIFM PNEC is: 0.0143 µg/L

- Revised PEC/PNECs (2015 IFRA VoU): North America and Europe < 1

1. Identification

1. **Chemical Name:** Terpinyl isobutyrate
2. **CAS Registry Number:** 7774-65-4
3. **Synonyms:** p-Menth-1-en-8-yl isobutyrate; 1-Methyl-1-(4-methyl-cyclohex-3-enyl)ethylisobutyrate; Propanoic acid, 2-methyl-, 1-methyl-1-(4-methyl-3-cyclohexen-1-yl)ethyl ester; 1-Methyl-1-(4-methylcyclohex-3-en-1-yl)ethyl 2-methylpropanoate; Terpinyl isobutyrate
4. **Molecular Formula:** C₁₄H₂₄O₂
5. **Molecular Weight:** 224.34
6. **RIFM Number:** 1188
7. **Stereochemistry:** Isomer not specified. One stereocenter and 2 total stereoisomers possible.

2. Physical data

1. **Boiling Point:** 263.02 °C (EPI Suite)
2. **Flash Point:** > 200 °F, > 93 °C (GHS)
3. **Log K_{ow}:** 5.25 (EPI Suite)
4. **Melting Point:** 32.35 °C (EPI Suite)
5. **Water Solubility:** 1.081 mg/L (EPI Suite)
6. **Specific Gravity:** 0.934 (RIFM)
7. **Vapor Pressure:** 0.00663 mmHg @ 20 °C (EPI Suite v4.0), 0.004 mm Hg 20C, 0.0117 mm Hg @ 25 °C (EPI Suite)
8. **UV Spectra:** No absorbance between 290 and 700 nm; molar absorption coefficient is below the benchmark (1000 L mol⁻¹ · cm⁻¹)
9. **Appearance/Organoleptic:** A clear liquid with a medium floral, green, herbal, spice, fatty, bergamot odor.*

*<http://www.thegoodscentscompany.com/data/rw1034861.html#toorgano>, retrieved 7/29/2015.

3. Exposure

1. **Volume of Use (worldwide band):** 0.1–1 metric tons per year (IFRA, 2015)
2. **95th Percentile Concentration in Hydroalcohols:** 0.000044% (RIFM, 2014a)
2. **Inhalation Exposure*:** 0.000012 mg/kg/day or 0.00086 mg/day (RIFM, 2014a)
3. **Total Systemic Exposure**:** 0.00018 mg/kg/day (RIFM, 2014a)

*95th percentile calculated exposure derived from concentration survey data in the Creme RIFM aggregate exposure model (Comiskey et al., 2015; Safford et al., 2015a; Safford et al., 2017; and Comiskey et al., 2017).

**95th percentile calculated exposure; assumes 100% absorption unless modified by dermal absorption data as reported in Section 4. It is derived from concentration survey data in the Creme RIFM aggregate exposure model and includes exposure via dermal, oral and inhalation routes whenever the fragrance ingredient is used in products that

include these routes of exposure (Comiskey et al., 2015; Safford et al., 2015a; Safford et al., 2017; and Comiskey et al., 2017).

4. Derivation of systemic absorption

1. **Dermal:** Assumed 100%
2. **Oral:** Assumed 100%
3. **Inhalation:** Assumed 100%

5. Computational toxicology evaluation

1. **Cramer Classification:** Class I, Low

| Expert Judgment | Toxtree v 2.6 | OECD QSAR Toolbox v 3.2 |
|-----------------|---------------|-------------------------|
| I | I | I |

2. Analogs Selected:

- a. **Genotoxicity:** α-Terpineol acetate (CAS # 80-26-2)
 - b. **Repeated Dose Toxicity:** Terpinyl acetate (isomer mixture; CAS # 8007-35-0)
 - c. **Developmental and Reproductive Toxicity:** Terpineol (CAS # 8000-41-7); isobutyric acid (CAS # 79-31-2)
 - d. **Skin Sensitization:** Terpinyl acetate (isomer mixture; CAS # 8007-35-0)
 - e. **Phototoxicity/Photoallergenicity:** None
 - f. **Local Respiratory Toxicity:** None
 - g. **Environmental Toxicity:** None
3. Read-across Justification: See Appendix below

6. Metabolism

Not considered for this risk assessment and therefore not reviewed except where it may pertain in specific endpoint sections as discussed below.

7. Natural occurrence (discrete chemical) or composition (NCS)

Terpinyl isobutyrate is not reported to occur in food by the VCF*. *VCF Volatile Compounds in Food: database/Nijssen, L.M.; Ingen-Visscher, C.A. van; Donders, J.J.H. (eds). – Version 15.1 – Zeist (The Netherlands): TNO Triskelion, 1963–2014. A continually updated database containing information on published volatile compounds that have been found in natural (processed) food products. Includes FEMA GRAS and EU-Flavis data.

8. IFRA standard

None.

9. REACH dossier

Pre-registered for 2010; No dossier available as of 2/14/2018.

10. Summary

10.1. Human health endpoint summaries

10.1.1. Genotoxicity

Based on the current existing data, terpinyl isobutyrate does not present a concern for genetic toxicity.

10.1.1.1. Risk assessment. Terpinyl isobutyrate was assessed in the BlueScreen assay and found negative for both cytotoxicity and genotoxicity, with and without metabolic activation, indicating a lack of concern regarding genotoxicity (RIFM, 2013c). There are no studies assessing the mutagenic activity of terpinyl isobutyrate. However, read-across can be made to α -terpineol acetate (CAS # 80-26-2; see Section 5). The mutagenic activity of α -terpineol acetate has been evaluated in a bacterial reverse mutation assay conducted in compliance with GLP regulations and in accordance with OECD TG 471 using the standard plate incorporation method. *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and *Escherichia coli* strain WP2uvrA were treated with α -terpineol acetate in dimethyl sulfoxide (DMSO) at concentrations up to 5000 μ g/plate. No increases in the mean number of revertant colonies were observed at any tested dose in the presence or absence of S9 (RIFM, 2014b). Under the conditions of the study, α -terpineol acetate was not mutagenic in the Ames test, and this can be extended to terpinyl isobutyrate.

There are no studies assessing the clastogenic activity of terpinyl isobutyrate. However, read-across can be made to α -terpineol acetate (CAS # 80-26-2; see Section 5). α -Terpineol acetate was evaluated in an *in vitro* micronucleus test conducted in compliance with GLP regulations and in accordance with OECD TG 487. Human peripheral blood lymphocytes were treated with α -terpineol acetate in DMSO at concentrations up to 225 μ g/mL in the presence and absence of metabolic activation (S9) at the 3-h and 24-h time points. A statistically significant increase in the frequency of binucleated cells with micronuclei (BNMN) was observed at 58.3 μ g/mL in the approximate 24-h treatment in the absence of S9. However, the %BNMN frequency (1.00%) at this concentration was within the historical control range. The percentage of cells with micronucleated binucleated cells in the test-substance tested groups was not significantly increased relative to vehicle control at any dose level for the 3-h treatment in the presence or absence of S9 (RIFM, 2014c). Under the conditions of the study, α -terpineol acetate was considered to be non-clastogenic in the *in vitro* micronucleus test (and this can be extended to terpinyl isobutyrate).

Based on the available data, α -terpineol acetate does not present a concern for genotoxic potential, and this can be extended to terpinyl isobutyrate.

Additional References: Oda et al., 1978; RIFM, 2012a; RIFM, 2013a; RIFM, 2013b.

Literature Search and Risk Assessment Completed On: 08/03/2017.

10.1.2. Repeated dose toxicity

The margin of exposure for terpinyl isobutyrate is adequate for the repeated dose toxicity endpoint at the current level of use.

10.1.2.1. Risk assessment. There are no repeated dose toxicity data on terpinyl isobutyrate. Read-across material terpinyl acetate (isomer mixture; CAS # 8007-35-0) has a dietary 20-week chronic toxicity

study conducted in Osborne-Mendel rats. Groups of 10 rats/sex/dose were administered diets containing 0, 1000, 2500, or 10000 ppm terpinyl acetate (isomer mixture), equivalent to 0, 50, 250, or 500 mg/kg/day, for 20 weeks. No effects on growth, no alterations in hematology, and no macroscopic or microscopic changes were observed up to the highest dose of 10000 ppm. The animals exposed to 10000 ppm in the diet consumed between 400 and 500 mg/kg/day terpinyl acetate. Thus, the NOAEL for repeated dose toxicity was considered to be 10000 ppm or 400 mg/kg/day (Hagan et al., 1967; data also available in Bar and Griepentrog, 1967 and ECHA Dossier: p-menth-1-en-8-yl acetate). Therefore, the terpinyl isobutyrate MOE for the repeated dose toxicity endpoint can be calculated by dividing the terpinyl acetate NOAEL in mg/kg/day by the total systemic exposure to terpinyl isobutyrate, 400/0.00018 or 2222222.

In addition, the total systemic exposure to terpinyl isobutyrate (0.18 μ g/kg/day) is below the TTC (30 μ g/kg bw/day) for the repeated dose toxicity endpoint of a Cramer Class I material at the current level of use.

Additional References: None.

Literature Search and Risk Assessment Completed On: 07/31/17.

10.1.3. Developmental and reproductive toxicity

The margin of exposure for terpinyl isobutyrate is adequate for the developmental and reproductive toxicity endpoints at the current level of use.

10.1.3.1. Risk assessment. There are no developmental toxicity data on terpinyl isobutyrate. Terpinyl isobutyrate is expected to hydrolyze to terpineol (CAS # 8000-41-7; see section 5) and isobutyric acid (CAS # 79-31-2; see section 5). There are sufficient developmental toxicity data on metabolite, terpineol. The metabolite isobutyric acid is expected to be directly excreted by phase II metabolism and hence does not contribute to the toxicity of terpinyl isobutyrate.

The metabolite terpineol has an OECD 422 gavage combined repeated dose toxicity study with a reproduction/developmental toxicity screening test conducted in Sprague Dawley rats. The rats were administered via gavage with test material terpineol at doses of 0, 60, 250, or 750 mg/kg/day in corn oil. The reproductive subgroup (main phase) consisted of 10 males and 10 females/dose (except for control males and at top dose: 5 males/dose). The toxicity subgroup consisted of 5 females/dose and 10 males. Main phase males and toxicity phase females were dosed daily for a minimum of 5 consecutive weeks. An additional 10 rats/sex/dose were dosed with the vehicle or 750 mg/kg/day for 5 weeks and then given 2 weeks of recovery before termination. There were no adverse effects towards the development of the fetus up to 250 mg/kg/day. At 750 mg/kg/day, no females became pregnant. It was considered that the testicular and epididymal effects observed in males receiving 750 mg/kg/day would have been sufficient to prevent fertilization. Thus, the NOAEL for the developmental toxicity endpoint was considered to be 250 mg/kg/day (ECHA Dossier: Terpineol). In another study, terpineol multiconstituent diluted in corn oil was administered by gavage to groups of mated female Sprague Dawley rats (20/dose) at the dose levels of 0, 60, 200, or 600 mg/kg/day from days 6–19 after mating. The test was conducted according to the OECD 414 protocol. Embryo-fetal growth was slightly reduced by maternal treatment as evidenced by the reduced mean male and female fetal weights at 600 mg/kg/day. In addition, the mean placental weight in this dose group was slightly low with differences attaining statistical significance. Mean placental, litter, and fetal weights at 60 or 200 mg/kg/day were unaffected by maternal treatment with terpineol. The incidence of major and minor abnormalities and skeletal variants showed no relationship to maternal treatment with terpineol. Thus, the NOAEL for the developmental toxicity was considered to be 200 mg/kg/day (ECHA Dossier: Terpineol). The most conservative NOAEL of 200 mg/kg/day was selected for the developmental toxicity endpoint.

Therefore, the terpinyl isobutyrate MOE for the developmental toxicity endpoint can be calculated by dividing the terpineol NOAEL in mg/kg/day by the total systemic exposure to terpinyl isobutyrate, 200/0.00018 or 1111111.

There are no reproductive toxicity data on terpinyl isobutyrate. Terpinyl isobutyrate is expected to hydrolyze to terpineol (CAS # 8000-41-7; see section 5) and isobutyric acid (CAS # 79-31-2; see section 5). There are sufficient reproductive toxicity data on metabolite, terpineol. The metabolite isobutyric acid is expected to be directly excreted by phase II metabolism and hence does not contribute to the toxicity of terpinyl isobutyrate.

The metabolite terpineol has an OECD 422 gavage combined repeated dose toxicity study with a reproduction/developmental toxicity screening test conducted in Sprague Dawley rats. The rats were administered via gavage with test material terpineol at doses of 0, 60, 250, or 750 mg/kg/day in corn oil. The reproductive subgroup (main phase) consisted of 10 males and 10 females/dose (except for control males and at top dose: 5 males/dose). The toxicity subgroup consisted of 5 females/dose and 10 males. Main phase males and toxicity phase females were dosed daily for a minimum of 5 consecutive weeks. An additional 5 rats/sex/dose were dosed with the vehicle or 750 mg/kg/day for 5 weeks and then given 2 weeks of recovery before termination. Testis weight was markedly lower in males receiving 750 mg/kg/day (58% of controls), and there was also an indication of low epididymal weights at this dose. This effect was also seen in the recovery group males. At 750 mg/kg/day, reduced numbers or complete absence of spermatozoa, accompanied by the presence of degenerate spermatogenic cells in the duct(s) were observed in the epididymides and were still present following the 2-week recovery period. Spermatocele granuloma(ta) that were seen in 2 males receiving 750 mg/kg/day and 1 receiving 60 mg/kg/day were not seen at the end of the recovery period. The significance of this change in the single male receiving 60 mg/kg/day is uncertain as spermatocele granuloma(ta) can occur spontaneously in rats of this age and considering the absence of other degenerative changes in the testes or epididymides of this animal. Moderate to severe seminiferous tubular atrophy/degeneration was seen in the testes of all animals dosed at 750 mg/kg/day, accompanied by minimal to moderate spermatid giant cells and minimal to slight seminiferous tubular vacuolation. Similar findings were still evident following the 2-week recovery period but at a lower incidence and severity suggesting a degree of recovery. There were no alterations in the female reproductive cycles or the reproductive organs up to the highest dose tested. Thus, the NOAEL for the reproductive toxicity endpoint was considered to be 250 mg/kg/day, based on impairment of male fertility at 750 mg/kg/day (ECHA Dossier: Terpineol). Therefore, the terpinyl isobutyrate MOE for the reproductive toxicity endpoint can be calculated by dividing the terpineol NOAEL in mg/kg/day by the total systemic exposure to terpinyl isobutyrate, 250/0.00018 or 1388889.

In addition, the total systemic exposure to terpinyl isobutyrate (0.18 µg/kg/day) is below the TTC (30 µg/kg bw/day) for the developmental and reproductive endpoints of a Cramer Class I material at the current level of use.

Additional References: None.

Literature Search and Risk Assessment Completed On: 07/31/17.

10.1.4. Skin sensitization

Based on the existing data and read-across analog terpinyl acetate (isomer mixture) (CAS # 8007-35-0), terpinyl isobutyrate does not present a concern for skin sensitization.

10.1.4.1. Risk assessment. Limited skin sensitization studies are available on terpinyl isobutyrate. Based on the available data on read-across analog terpinyl acetate (isomer mixture) (CAS # 8007-35-0; see section 5), terpinyl isobutyrate does not present a concern for

skin sensitization. The chemical structure of these materials would indicate that they could possibly react with skin proteins with little to no reaction under physiological conditions. In a murine local lymph node assay, read-across analog terpinyl acetate (isomer mixture) was found to be negative up to maximum tested concentration of 100%, which resulted in a Stimulation Index (SI) of 2.4 (RIFM, 2012b). In guinea pigs, an open epicutaneous test with read-across analog terpinyl acetate (isomer mixture) did not present reactions indicative of sensitization (Klecak, 1985). In a human maximization test, no skin sensitization reactions were observed with 10% or 6900 µg/cm² terpinyl isobutyrate in petrolatum (RIFM, 1982). In a human maximization test, no skin sensitization reactions were observed with 5% or 3450 µg/cm² read-across analog terpinyl acetate (isomer mixture) in petrolatum (RIFM, 1971). Based on weight of evidence from structural analysis, human studies, and read-across analog terpinyl acetate (isomer mixture), terpinyl isobutyrate does not present a concern for skin sensitization.

Additional References: None.

Literature Search and Risk Assessment Completed On: 08/07/17.

10.1.5. Phototoxicity/photoallergenicity

Based on available UV/Vis spectra, terpinyl isobutyrate would not be expected to present a concern for phototoxicity or photoallergenicity.

10.1.5.1. Risk assessment. There are no phototoxicity studies available for terpinyl isobutyrate in experimental models. UV/Vis absorption spectra indicate no significant absorption between 290 and 700 nm. The corresponding molar absorption coefficient is well below the benchmark of concern for phototoxicity and photoallergenicity (Henry et al., 2009). Based on lack of absorbance, terpinyl isobutyrate does not present a concern for phototoxicity or photoallergenicity.

10.1.5.2. UV spectra analysis. The available UV/Vis spectra (OECD TG 101) for terpinyl isobutyrate indicate no significant absorbance between 290 and 700 nm. The molar absorption coefficient is below the benchmark of concern for phototoxic effects, 1000 L mol⁻¹ · cm⁻¹ (Henry et al., 2009).

Additional References: None.

Literature Search and Risk Assessment Completed On: 07/07/17.

10.1.6. Local respiratory toxicity

The margin of exposure could not be calculated due to lack of appropriate data. The material terpinyl isobutyrate exposure level is below the Cramer Class I TTC value for inhalation exposure local effects.

10.1.6.1. Risk assessment. There are no inhalation data available on terpinyl isobutyrate. Based on the Creme RIFM model, the inhalation exposure is 0.00086 mg/day. This exposure is 1628 times lower than the Cramer Class I TTC value of 1.4 mg/day (based on human lung weight of 650 g; Carthew et al., 2009); therefore, the exposure at the current level of use is deemed safe.

Additional References: None.

Literature Search and Risk Assessment Completed On: 08/03/2017.

10.2. Environmental endpoint summary

10.2.1. Screening-level assessment

A screening-level risk assessment of terpinyl isobutyrate was performed following the RIFM Environmental Framework (Salvito et al., 2002), which provides 3 tiered levels of screening for aquatic risk. In

Tier 1, only the material's regional VoU, its log K_{ow} , and its molecular weight are needed to estimate a conservative risk quotient (RQ), expressed as the ratio Predicted Environmental Concentration/Predicted No Effect Concentration (PEC/PNEC). A general QSAR with a high uncertainty factor applied is used to predict fish toxicity, as discussed in [Salvito et al. \(2002\)](#). In Tier 2, the RQ is refined by applying a lower uncertainty factor to the PNEC using the ECOSAR model ([US EPA, 2012b](#)), which provides chemical class-specific ecotoxicity estimates. Finally, if necessary, Tier 3 is conducted using measured biodegrada-

10.2.2.2. *Ecotoxicity*. No data available.

10.2.2.3. *Other available data*. Terpinyl isobutyrate has been pre-registered for REACH with no additional data at this time.

10.2.3. Risk assessment refinement

Ecotoxicological data and PNEC derivation (all endpoints reported in mg/L; PNECs in $\mu\text{g/L}$).

Endpoints used to calculate PNEC are underlined.

| | | | | | | |
|--|---------------|-------|--------------|-----------|----------|---|
| RIFM Framework | | | | | | |
| Screening-level (Tier 1) | <u>0.4502</u> | | | 1,000,000 | 0.004502 | |
| ECOSAR Acute Endpoints (Tier 2) Ver 1.11 | 0.381 | 0.560 | <u>0.143</u> | 10,000 | 0.0143 | Esters |
| ECOSAR Acute Endpoints (Tier 2) Ver 1.11 | 0.224 | 0.172 | 0.442 | | | Neutral Organic SAR (Baseline toxicity) |

tion and ecotoxicity data to refine the RQ, thus allowing for lower PNEC uncertainty factors. The data for calculating the PEC and PNEC for this safety assessment are provided in the table below. For the PEC, the range from the most recent IFRA Volume of Use Survey is reviewed. The PEC is then calculated using the actual regional tonnage, not the extremes of the range. Following the RIFM Environmental Framework, terpinyl isobutyrate was identified as a fragrance material with the potential to present a possible risk to the aquatic environment (i.e., its screening level PEC/PNEC > 1).

A screening-level hazard assessment using EPI Suite v4.11 ([US EPA, 2012a](#)) identified terpinyl isobutyrate as possibly persistent but not bioaccumulative based on its structure and physical-chemical properties. This screening-level hazard assessment considers the potential for a material to be persistent *and* bioaccumulative *and* toxic, or very persistent *and* very bioaccumulative as defined in the Criteria Document ([Api et al., 2015](#)). As noted in the Criteria Document, the screening criteria applied are the same as those used in the EU for REACH ([ECHA, 2012](#)). For persistence, if the EPI Suite model BIOWIN 3 predicts a value < 2.2 and either BIOWIN 2 or BIOWIN 6 predicts a value < 0.5, then the material is considered potentially persistent. A material would be considered potentially bioaccumulative if the EPI Suite model BCFBAF predicts a fish BCF ≥ 2000 L/kg. Ecotoxicity is determined in the above screening-level risk assessment. If, based on these model outputs (Step 1), additional assessment is required, a WoE-based review is then performed (Step 2). This review considers available data on the material's physical-chemical properties, environmental fate (e.g., OECD Guideline biodegradation studies or die-away studies), fish bioaccumulation, and higher-tier model outputs (e.g., US EPA's BIOWIN and BCFBAF found in EPI Suite v4.11). Data on persistence and bioaccumulation are reported below and summarized in the Environmental Safety Assessment section prior to Section 1.

10.2.2. Risk assessment

Based on the current Volume of Use (2015), terpinyl isobutyrate presents a risk to the aquatic compartment in the screening-level assessment.

10.2.2.1. *Biodegradation*. No data available.

Exposure information and PEC calculation (following RIFM Environmental Framework: [Salvito et al., 2002](#)).

| Exposure | Europe (EU) | North America (NA) |
|--|---------------|--------------------|
| Log K_{ow} Used | 5.25 | 5.25 |
| Biodegradation Factor Used | 0 | 0 |
| Dilution Factor | 3 | 3 |
| Regional Volume of Use Tonnage Band | < 1 | < 1 |
| Risk Characterization: PEC/PNEC | < 1 | < 1 |

Based on available data, the RQ for this material is < 1. No further assessment is necessary.

The RIFM PNEC is 0.0143 $\mu\text{g/L}$. The revised PEC/PNECs for EU and NA are < 1 and therefore, does not present a risk to the aquatic environment at the current reported volumes of use.

Literature Search and Risk Assessment Completed On: 8/2/17.

11. Literature search*

- **RIFM Database:** Target, Fragrance Structure Activity Group materials, other references, JECFA, CIR, SIDS
- **ECHA:** <http://echa.europa.eu/>
- **NTP:** <https://ntp.niehs.nih.gov/>
- **OECD Toolbox**
- **SciFinder:** <https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf>
- **PubMed:** <http://www.ncbi.nlm.nih.gov/pubmed>
- **TOXNET:** <http://toxnet.nlm.nih.gov/>
- **IARC:** <http://monographs.iarc.fr>
- **OECD SIDS:** <http://webnet.oecd.org/hpv/ui/Default.aspx>
- **EPA ACToR:** <https://actor.epa.gov/actor/home.xhtml>
- **US EPA HPVIS:** https://ofmpub.epa.gov/opthpv/public_search

publicdetails?submission_id=24959241&ShowComments=Yes&sqlstr=null&recordcount=0&User_title=DetailQuery%20Results&EndPointRpt=Y#submission

- **Japanese NITE:** <http://www.safe.nite.go.jp/english/db.html>
- **Japan Existing Chemical Data Base (JECDB):** http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp
- **Google:** <https://www.google.com>
- **ChemIDplus:** <https://chem.nlm.nih.gov/chemidplus/>

Search keywords: CAS number and/or material names.
*Information sources outside of RIFM's database are noted as appropriate in the safety assessment. This is not an exhaustive list.

12. Conflicts of interest

The authors declare that they have no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.fct.2018.10.014>.

Appendix

Read-across justification

Methods

The read-across analogs were identified following the strategy for structuring and reporting a read-across prediction of toxicity described in Schultz et al. (2015). The strategy is also consistent with the guidance provided by OECD within Integrated Approaches for Testing and Assessment (OECD, 2015) and the European Chemical Agency read-across assessment framework (ECHA, 2016).

- First, materials were clustered based on their structural similarity. Second, data availability and data quality on the selected cluster was examined. Third, appropriate read-across analogs from the cluster were confirmed by expert judgment.
- Tanimoto structure similarity scores were calculated using FCFC4 fingerprints (Rogers and Hahn, 2010).
- The physical–chemical properties of the target substance and the read-across analogs were calculated using EPI Suite v4.11 (US EPA, 2012a).
- J_{\max} values were calculated using RIFM's skin absorption model (SAM). The parameters were calculated using the consensus model (Shen et al., 2014).
- DNA binding, mutagenicity, genotoxicity alerts, and oncologic classification predictions were generated using OECD QSAR Toolbox v3.4 (OECD, 2015).
- ER binding and repeat dose categorization were generated using OECD QSAR Toolbox v3.4 (OECD, 2015).
- Developmental toxicity was predicted using CAESAR v2.1.7 (Cassano et al., 2010) and skin sensitization was predicted using Toxtree 2.6.13.
- Protein binding was predicted using OECD QSAR Toolbox v3.4 (OECD, 2015).

• The major metabolites for the target and read-across analogs were determined and evaluated using OECD QSAR Toolbox v3.4 (OECD, 2015).

| | Target Material | Read-across Material | | | |
|--|----------------------|-----------------------------|---|---|---|
| Principal Name | Terpinyl isobutyrate | α -Terpineol acetate | Terpinyl acetate (isomer mixture) | Terpineol | Isobutyric acid |
| CAS No. | 7774-65-4 | 80-26-2 | 8007-35-0 | 8000-41-7 | 79-31-2 |
| Structure | | | | | |
| Similarity (Tanimoto Score) | | 0.77 | 0.77 | NA | NA |
| Read-across Endpoint | | • Genotoxicity | • Skin sensitization • Repeated dose | • Developmental and reproductive toxicity | • Developmental and reproductive toxicity |
| Molecular Formula | $C_{14}H_{24}O_2$ | $C_{12}H_{20}O_2$ | $C_{12}H_{20}O_2$ | $C_{10}H_{18}O$ | $C_4H_8O_2$ |
| Molecular Weight | 224.35 | 196.26 | 196.26 | 154.25 | 88.11 |
| Melting Point ($^{\circ}C$, EPI Suite) | 32.35 | 21.47 | 21.47 | 12.36 | -8.29 |
| Boiling Point ($^{\circ}C$, EPI Suite) | 263.02 | 238.66 | 238.66 | 214.38 | 153.79 |
| Vapor Pressure (Pa @ 25 $^{\circ}C$, EPI Suite) | 1.56 | 6.63 | 6.63 | 2.62 | 436 |
| Log K_{OW} (KOWWIN v1.68 in EPI Suite) | 5.25 | 3.96 | 3.96 | 3.28 | 0.94 |
| Water Solubility (mg/L, @ 25 $^{\circ}C$, WSKOW v1.42 in EPI Suite) | 1.081 | 18.97 | 18.97 | 1980 | 167000 |
| J_{\max} (mg/cm 2 /h, SAM) | 49.170 | 235.584 | 235.584 | 205.463 | 3228.89 |
| Henry's Law (Pa·m 3 /mol, Bond Method, EPI Suite) | 1.84E+002 | 1.04E+002 | 1.04E+002 | 1.60E+000 | 9.78E-002 |

Genotoxicity

| | | |
|---|--|---|
| DNA Binding (OASIS v1.4, QSAR Toolbox v3.4) | <ul style="list-style-type: none"> • No alert found | <ul style="list-style-type: none"> • Schiff base formation • Nucleophilic attack • Acylation |
| DNA Binding (OECD QSAR Toolbox v3.4) Carcinogenicity (ISS) | <ul style="list-style-type: none"> • No alert found • Non-carcinogen (low reliability) | <ul style="list-style-type: none"> • No alert found • Non-carcinogen (low reliability) |
| DNA Binding (Ames, MN, CA, OASIS v1.1) | <ul style="list-style-type: none"> • No alert found | <ul style="list-style-type: none"> • No alert found |
| <i>In Vitro</i> Mutagenicity (Ames, ISS) | <ul style="list-style-type: none"> • No alert found | <ul style="list-style-type: none"> • No alert found |
| <i>In Vivo</i> Mutagenicity (Micronucleus, ISS) | <ul style="list-style-type: none"> • No alert found | <ul style="list-style-type: none"> • No alert found |
| Oncologic Classification | <ul style="list-style-type: none"> • Not classified | <ul style="list-style-type: none"> • Not classified |

Repeated dose toxicity

| | | |
|----------------------|------------------|------------------|
| Repeated Dose (HESS) | •Not categorized | •Not categorized |
|----------------------|------------------|------------------|

Reproductive and Developmental Toxicity

| | | | |
|--|--|--|--|
| ER Binding (OECD QSAR Toolbox v3.4) | <ul style="list-style-type: none"> • Non-binder, without OH or NH₂ | <ul style="list-style-type: none"> • Non-binder, without OH or NH₂ | <ul style="list-style-type: none"> • Non-binder, without OH or NH₂ |
| Developmental Toxicity (CAESAR v2.1.6) | <ul style="list-style-type: none"> • Non-toxicant (low reliability) | <ul style="list-style-type: none"> • Toxicant (good reliability) | <ul style="list-style-type: none"> • Toxicant (low reliability) |

Skin Sensitization

| | | |
|---|---------------------------|---------------------------|
| Protein binding by OASIS v1.1 | •No alert found | •No alert found |
| Protein binding by OECD | •No alert found | •No alert found |
| Protein binding potency | •Not possible to classify | •Not possible to classify |
| Protein binding alerts for skin sensitization by OASIS v1.1 | • No alert found | • No alert found |
| Skin Sensitization model (CAESAR) (version 2.1.6) | • No alert found | • No alert found |

Metabolism

| | | | | | |
|--|-------------------------|-------------------------|-------------------------|-------------------------|----------------|
| Rat Liver S9 Metabolism Simulator and Structural Alerts for Metabolites (OECD QSAR Toolbox v3.4) | See Supplemental Data 1 | See Supplemental Data 2 | See Supplemental Data 3 | See Supplemental Data 4 | No metabolites |
|--|-------------------------|-------------------------|-------------------------|-------------------------|----------------|

Summary

There are insufficient toxicity data on terpinyl isobutyrate (CAS # 7774-65-4). Hence, *in silico* evaluation was conducted to determine read-across analogs for this material. Based on structural similarity, reactivity, metabolism, physical–chemical properties, and expert judgment, α -terpineol acetate (CAS # 80-26-2), terpinyl acetate (isomer mixture) (CAS # 8007-35-0), terpineol (CAS # 8000-41-7) and isobutyric acid (CAS # 79-31-2) were identified as read-across materials with sufficient data for toxicological evaluation.

Conclusions

- α -Terpineol acetate (CAS # 80-26-2) was used as a read-across analog for the target material terpinyl isobutyrate (CAS # 7774-65-4) for the genotoxicity endpoint.
 - o The target substance and the read-across analog are structurally similar and belong to the class of terpene esters.

- o The target substance and the read-across analog share a cyclic unsaturated tertiary alcohol fragment.
 - o The key difference between the target substance and the read-across analog is that the target substance has an isobutyrate acid fragment and the read-across analog has an acetate fragment. This structural difference is toxicologically insignificant.
 - o The similarity between the target substance and the read-across analog is indicated by the Tanimoto score. The Tanimoto score is mainly driven by the cyclic unsaturated tertiary alcohol fragment. Differences between the structures that affect the Tanimoto score are toxicologically insignificant.
 - o The physical–chemical properties of the target substance and the read-across analog are sufficiently similar to enable comparison of their toxicological properties.
 - o According to the OECD QSAR Toolbox v3.4, structural alerts for toxicological endpoints are consistent between the target substance and the read-across analog.
 - o The read-across analog has an alert for Schiff base formation by DNA binding model by OASIS. This shows that the read-across analog is more reactive than the target substance. The data described in the genotoxicity section shows that the read-across analog does not pose a concern for genetic toxicity. Therefore, the alert will be superseded by the availability of the data.
 - o The target substance and the read-across analog are expected to be metabolized similarly, as shown by the metabolism simulator.
 - o The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target material.
 - Terpinyl acetate (isomer mixture) (CAS # 8007-35-0) was used as a read-across analog for the target material terpinyl isobutyrate (CAS # 7774-65-4) for the skin sensitization endpoint.
 - o The target substance and the read-across analog are structurally similar and belong to the class of terpene esters.
 - o The target substance and the read-across analog share a cyclic unsaturated tertiary alcohol fragment.
 - o The key difference between the target substance and the read-across analog is that the target substance has an isobutyrate acid fragment and the read-across analog has an acetate fragment. This structural difference is toxicologically insignificant.
 - o The similarity between the target substance and the read-across analog is indicated by the Tanimoto score. The Tanimoto score is mainly driven by the cyclic unsaturated tertiary alcohol fragment. Differences between the structures that affect the Tanimoto score are toxicologically insignificant.
 - o The physical–chemical properties of the target substance and the read-across analog are sufficiently similar to enable comparison of their toxicological properties.
 - o According to the OECD QSAR Toolbox v3.4, structural alerts for toxicological endpoints are consistent between the target substance and the read-across analog.
 - o The target substance and the read-across analog are expected to be metabolized similarly, as shown by the metabolism simulator.
 - o The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target material.
 - Terpinyl acetate (isomer mixture) (CAS # 8007-35-0) was used as a read-across analog for the target material terpinyl isobutyrate (CAS # 7774-65-4) for the repeated dose toxicity endpoint.
 - o The target substance and the read-across analog are structurally similar and belong to the class of terpene esters.
 - o The target substance and the read-across analog share a cyclic unsaturated tertiary alcohol fragment.
 - o The key difference between the target substance and the read-across analog is that the target substance has an isobutyrate acid fragment and the read-across analog has an acetate fragment. This structural difference is toxicologically insignificant.
 - o The similarity between the target substance and the read-across analog is indicated by the Tanimoto score. The Tanimoto score is mainly driven by the cyclic unsaturated tertiary alcohol fragment. Differences between the structures that affect the Tanimoto score are toxicologically insignificant.
 - o The physical–chemical properties of the target substance and the read-across analog are sufficiently similar to enable comparison of their toxicological properties.
 - o According to the OECD QSAR Toolbox v3.4, structural alerts for toxicological endpoints are consistent between the target substance and the read-across analog.
 - o The target substance and the read-across analog are expected to be metabolized similarly, as shown by the metabolism simulator.
 - o The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target material.
- Metabolism. Metabolism of the target material terpinyl isobutyrate (CAS # 7774-65-4) was predicted using the Rat Liver S9 Metabolism Simulator (OECD QSAR Toolbox v3.4). The target material is metabolized to α -terpineol (CAS # 98-55-5) and isobutyric acid (CAS # 79-31-2) in the first step with 0.95% probability. α -Terpineol is an isomer of terpineol (CAS # 8000-41-7). Also, isobutyric acid is structurally similar to acetic acid. Hence, terpineol (CAS # 8000-41-7) and isobutyric acid (CAS # 79-31-2) can be used as read-across analogs for the target material. Read-across analogs terpineol (CAS # 8000-41-7) and isobutyric acid (CAS # 79-31-2) were out of domain for the *in vivo* rat and out of domain for the *in vitro* rat S9 simulator (OASIS TIMES v2.27.19). However, based on expert judgment, the model's domain exclusion was overridden, and justification is provided.
- Read-across alcohol terpineol (CAS # 8000-41-7) and read-across acid isobutyric acid (CAS # 79-31-2) are used as read-across analogs for target ester terpinyl isobutyrate (CAS # 7774-65-4) for reproductive and developmental toxicity endpoint.
 - o The products of ester hydrolysis (corresponding alcohol and acid) are used as read-across analogs for the target ester for the endpoints indicated in the table.
 - o The read-across materials are major metabolites or analogs of the major metabolites of the target.
 - o Structural differences between the target substance and the read-across analog are mitigated by the fact that the target could be metabolically hydrolyzed to the read-across analogs. Therefore, the toxicity profile of the target is expected to be similar to that of its metabolites.
 - o The target substance and the read-across analog have similar physical–chemical properties. Any differences in the physical–chemical properties of the target substance and the read-across analogs are toxicologically insignificant.
 - o According to the QSAR OECD Toolbox v3.4, structural alerts for the endpoints evaluated are consistent between the target substance and the read-across analog.

- o The read-across analogs are predicted to be toxicants by the CAESAR model for developmental toxicity. The data described in the developmental toxicity section above shows that the read-across analogs have an adequate margin of exposure at the current level of use. Therefore, the alert will be superseded by the availability of the data.
- o The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target substance.

References

- Api, A.M., Belsito, D., Bruze, M., Cadby, P., Calow, P., Dagli, M.L., Dekant, W., Ellis, G., Fryer, A.D., Fukayama, M., Griem, P., Hickey, C., Kromidas, L., Lalko, J.F., Liebler, D.C., Miyachi, Y., Politano, V.T., Renskers, K., Ritacco, G., Salvito, D., Schultz, T.W., Sipes, I.G., Smith, B., Vitale, D., Wilcox, D.K., 2015. Criteria for the research institute for fragrance materials, inc. (RIFM) safety evaluation process for fragrance ingredients. *Food Chem. Toxicol.* 82, S1–S19.
- Bar, V.F., Griepentrog, F., 1967. Die Situation in der gesundheitlichen Beurteilung der Aromatisierungsmittel Fur Lebensmittel. (Where we stand concerning the evaluation of flavoring substances from the viewpoint of health). *Medizin Ernahr* 8, 244–251.
- Carthew, P., Clapp, C., Gutsell, S., 2009. Exposure based waiving: the application of the toxicological threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. *Food Chem. Toxicol.* 47 (6), 1287–1295.
- Cassano, A., Manganaro, A., Martin, T., Young, D., Piclin, N., Pintore, M., Bigoni, D., Benfenati, E., 2010. CAESAR models for developmental toxicity. *Chem. Cent. J.* 4 (Suppl 1), S4.
- Comiskey, D., Api, A.M., Barratt, C., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Safford, B., Smith, B., Tozer, S., 2015. Novel database for exposure to fragrance ingredients in cosmetics and personal care products. *Regul. Toxicol. Pharmacol.* 72 (3), 660–672.
- Comiskey, D., Api, A.M., Barrett, C., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Rose, J., Safford, B., Smith, B., Tozer, S., 2017. Integrating habits and practices data for soaps, cosmetics and air care products into an existing aggregate exposure model. *Regul. Toxicol. Pharmacol.* 88, 144–156.
- ECHA, 2012. Guidance on Information Requirements and Chemical Safety Assessment Chapter R.11: PBT Assessment, November 2012 v1.1. <http://echa.europa.eu/>.
- ECHA, 2016. European chemical agency read-across assessment framework. ECHA read-across assessment framework. www.echa.europa.eu/documents/10162/13628/raaf_en.pdf.
- Hagan, E.C., Hansen, W.H., Fitzhugh, O.G., Jenner, P.M., Jones, W.I., Taylor, J.M., Long, E.L., Nelson, A.M., Brouwer, J.B., 1967. Food flavorings and compounds of related structure. II. Subacute and chronic toxicity. *Food Chem. Toxicol.* 5 (2), 141–157.
- Henry, B., Foti, C., Alsante, K., 2009. Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule? *J. Photochem. Photobiol. B Biol.* 96 (1), 57–62.
- IFRA (International Fragrance Association), 2015. Volume of Use Survey, February 2015. OECD (2012). The OECD QSAR Toolbox, V 3.4. <http://www.qsartoolbox.org/>.
- Klecak, G., 1985. The Freund's complete adjuvant test and the open epicutaneous test. In: *Problems in Dermatology* Vol. 14. pp. 152–171.
- Oda, Y., Hamano, Y., Inoue, K., Yamamoto, H., Niihara, T., Kunita, N., 1978. Mutagenicity of food flavours in bacteria (1st Report). *Osaka-furitsu Koshu Eisei Kenkyu Hokoku Shokuhin Eisei Hen.* 9, 177–181.
- OECD, 2015. Guidance Document on the Reporting of Integrated Approaches to Testing and Assessment. ENV/JM/HA(2015)7. Retrieved from. <http://www.oecd.org/>.
- RIFM (Research Institute for Fragrance Materials, Inc), 1971. Appraisal of Sensitizing Powers by Maximization Testing in Humans. Report to RIFM. RIFM report number 1805. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 1982. Report on Human Maximization Studies. Report to RIFM. RIFM report number 1643. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2012a. Bacterial Reverse Mutation Test with Alpha-terpineol Acetate. Unpublished Report from International Flavors and Fragrances. RIFM report number 65207. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2012b. Assessment of Contact Hypersensitivity to Alpha-terpineol Acetate (Mono-constituent) in the Mouse (Local Lymph Node Assay). Unpublished Report from International Flavors and Fragrances. RIFM report number 65208. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2013a. Report on the Testing of Alpha-terpineol Acetate in the BlueScreen HC Assay (-/+ S9 Metabolic Activation). RIFM report number 65424. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2013b. Report on the Testing of Alpha-terpineol Acetate in the BlueScreen HC Assay (-/+ S9 Metabolic Activation). RIFM report number 65507. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2013c. Report on the Testing of Terpinyl Isobutyrate in the BlueScreen HC Assay (-/+ S9 Metabolic Activation). RIFM report number 66147. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2014a. Exposure Survey 05, September 2014.
- RIFM (Research Institute for Fragrance Materials, Inc), 2014b. Alpha-terpineol Acetate: Bacterial Reverse Mutation Assay. RIFM report number 67285. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc), 2014c. Alpha-terpineol Acetate: in Vitro Micronucleus Assay in Human Peripheral Blood Lymphocytes. RIFM report number 67577. RIFM, Woodcliff Lake, NJ, USA.
- Rogers, D., Hahn, M., 2010. Extended-connectivity fingerprints. *J. Chem. Inf. Model.* 50 (5), 742–754.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Smith, B., Thomas, R., Tozer, S., 2015. Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products. *Regul. Toxicol. Pharmacol.* 72, 673–682.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Rose, J., Smith, B., Tozer, S., 2017. Application of the expanded Creme RIFM consumer exposure model to fragrance ingredients in cosmetic, personal care and air care products. *Regul. Toxicol. Pharmacol.* 86, 148–156.
- Salvito, D.T., Senna, R.J., Federle, T.W., 2002. A Framework for prioritizing fragrance materials for aquatic risk assessment. *Environ. Toxicol. Chem.* 21 (6), 1301–1308.
- Schultz, T.W., Amcoff, P., Berggren, E., Gautier, F., Klaric, M., Knight, D.J., Mahony, C., Schwarz, M., White, A., Cronin, M.T., 2015. A strategy for structuring and reporting a read-across prediction of toxicity. *Regul. Toxicol. Pharmacol.* 72 (3), 586–601.
- Shen, J., Kromidas, L., Schultz, T., Bhatia, S., 2014. An *in silico* skin absorption model for fragrance materials. *Food Chem. Toxicol.* 74, 164–176.
- US EPA, 2012a. Estimation Programs Interface Suite for Microsoft Windows, v4.0–v4.11. United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2012b. The ECOSAR (ECOLOGICAL Structure Activity Relationship) Class Program for Microsoft Windows, v1.11. United States Environmental Protection Agency, Washington, DC, USA.